Latest News & Features
Americas
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities. 28 March 2013
Sectors
Oxitec’s pioneering insect sterilisation technique could eradicate dengue fever and malaria and cut crop damage worldwide. LSIPR spoke to CEO Hadyn Parry about the company’s development and its approach to protecting its inventions. 28 February 2013
Asia
Sugen’s patent for anti-cancer drug sunitinib has been revoked by the Indian Patent Office. Ranjna Mehta-Dutt and Swarup Kumar at Remfry & Sagar explain the details of the matter. 1 February 2013
Big Pharma
It seems an unlikely place for innovation, but Lille and its surroundings play host to a burgeoning life sciences industry. LSIPR visited to find out more. 1 February 2013
Asia-Pacific
The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues. 1 February 2013
Americas
The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications. 1 December 2012
Americas
The status of patentability for new dosage regimes in Mexico is unclear, but there have been some positive signs, says Pablo Fuentes. 1 May 2012
Big Pharma
Brazil’s IP system has struggled to keep pace with its economic growth, but as Otto Licks and Marcela Trigo explain, there are some promising signs. 1 May 2012
Americas
The system governing preliminary injunctions for pharmaceutical patent infringement should be revised to
stave off potential frivolous cases, say Hedwig Lindner and Manuel Morante. 1 May 2012
article
LSIPR talks to Matt McBride about how Science IP can help businesses ensure their patent plans get off to the best possible start. 1 May 2012